Estimating the Treatment of Carbapenem-Resistant Enterobacteriaceae Infections in the United States Using Antibiotic Prescription Data

Open Forum Infectious Diseases

Volumn 6, Issue 8, 2019, Pages

  Clancy, Cornelius J ^a,b   Potoski, Brian A ^a   Buehrle, Deanna ^b   Nguyen, M Hong ^a  

^a UNIVERSITY OF PITTSBURGH   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

carbapenem resistant Enterobacteriaceae; ceftazidime avibactam; meropenem vaborbactam; plazomicin; polymyxins

Indexed keywords

ANTIBIOTIC AGENT; AVIBACTAM; AZITHROMYCIN; AZTREONAM; CARBAPENEM; CEFEPIME; CEFTAZIDIME; CIPROFLOXACIN; COLISTIN; FOSFOMYCIN; IMIPENEM; INFLUENZA VACCINE; LIRAGLUTIDE; MEROPENEM; MEROPENEM PLUS VABORBACTAM; MINOCYCLINE; NITROFURANTOIN; PLAZOMICIN; POLYMYXIN B; RIFAMPICIN; TIGECYCLINE; TRIMETHOPRIM;

ABDOMINAL INFECTION; ANTIBIOTIC RESISTANCE; ARTICLE; BACTEREMIA; BACTERIAL INFECTION; CARBAPENEM-RESISTANT ENTEROBACTERIACEAE; DRUG INTERACTION; ENTEROBACTERIACEAE; ESCHERICHIA COLI; HOSPITALIZATION; HUMAN; IMMUNE RESPONSE; NEPHROTOXICITY; NONHUMAN; PHARMACIST; PNEUMONIA; PRESCRIPTION; PRIORITY JOURNAL; UNITED STATES; URINARY TRACT INFECTION;

EID: 85076640159     PISSN: None     EISSN: 23288957     Source Type: Journal    
DOI: 10.1093/ofid/ofz344     Document Type: Article

References (29)

1. Centers for Disease Control and Prevention. Antibiotic Resistance Threats in the United States, 2013. Available at: https://www.cdc.gov/drugresistance/pdf/ar-threats-2013-508.pdf. Accessed 14 June 2019.
2. Temkin E, Fallach N, Almagor J, et al. Estimating the number of infections caused by antibiotic-resistant Escherichia coli and Klebsiella pneumoniae in 2014: a modelling study. Lancet Glob Health 2018; 6:e969-79.
3. Zilberberg MD, Nathanson BH, Sulham K, et al. Carbapenem resistance, inappropriate empiric treatment and outcomes among patients hospitalized with Enterobacteriaceae urinary tract infection, pneumonia and sepsis. BMC Infect Dis 2017; 17:279.
4. New York State Department of Health. Hospital-aquired infections, New York State 2014. Available at: https://www.health.ny.gov/statistics/facilities/hospital/hospital-acquired-infections/2014/docs/hospital-acquired-infection.pdf. Accessed 9 April 2019.
5. Tacconelli E, Carrara E, Savoldi A, et al. Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis. Lancet Infect Dis 2018; 18:318-27.
6. Boucher HW, Talbot GH, Bradley JS, et al. Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America. Clin Infect Dis 2009; 48:1-12.
7. Shields RK, Nguyen MH, Chen L, et al. Ceftazidime-avibactam is superior to other treatment regimens against carbapenem-resistant Klebsiella pneumoniae bacteremia. Antimicrob Agents Chemother 2017; 61:e00883-17.
8. van Duin D, Lok JJ, Earley M, et al. Colistin versus ceftazidime-avibactam in the treatment of infections due to carbapenem-resistant Enterobacteriaceae. Clin Infect Dis 2018; 66:163-71.
9. Wunderink RG, Giamarellos-Bourboulis EJ, Rahav G, et al. Effect and safety of meropenem-vaborbactam versus best-available therapy in patients with carbapenem-resistant Enterobacteriaceae infections: the TANGO II randomized clinical trial. Infect Dis Ther 2018; 7:439-55.
10. McKinnell JA, Dwyer JP, Talbot GH, et al. Plazomicin for infections caused by carbapenem-resistant Enterobacteriaceae. N Engl J Med 2019; 380:791-3.
11. Tumbarello M, Trecarichi EM, Corona A, et al. Efficacy of ceftazidime-avibactam salvage therapy in patients with infections caused by Klebsiella pneumoniae carbapenemase-producing K. pneumoniae. Clin Infect Dis 2019; 68:355-64.
12. Shlaes DM. You too, Achaogen Available at: http://antibiotics-theperfectstorm. blogspot.com/2018/07/you-too-achaogen.html. Accessed 9 January 2019.
13. Tong A. Low sales, high cost: Melinta slashes HQ research staff as it struggles to grow antibiotics revenue. Endpoints News, 2018. Available at: https://endpts.com/low-sales-high-cost-melinta-slashes-hq-research-staff-as-it-struggles-to-growantibiotics-revenue/. Accessed 14 June 2019.
14. Rex JH. Scary, scarier, scariest (part 2): What can you do about it 2019. Blog: AMR Solutions. Available at http://amr.solutions/blog/scary-scarier-scariestpart-2-what-can-you-do-about-it. Accessed 14 June 2019.
15. Carroll J. Once picked as a $500M winner, bankrupt Achaogen auctions off its antibiotic for a fraction of that. Endpoints News 2019. https://endpts.com/oncepicked-as-a-500m-winner-bankrupt-achaogen-auctions-off-its-antibiotic-for-afraction-of-that/. Accessed 14 June 2019.
16. Santevecchi BA, Smith TT, MacVane SH. Clinical experience with ceftazidime/avibactam for treatment of antibiotic-resistant organisms other than Klebsiella pneumoniae. Int J Antimicrob Agents 2018; 51:629-35.
17. Temkin E, Torre-Cisneros J, Beovic B, et al. Ceftazidime-avibactam as salvage therapy for infections caused by carbapenem-resistant organisms. Antimicrob Agents Chemother 2017; 61:e01964-16.
18. Cubist. Corporate Presentation September 2012. Available at: http://www.snl. com/interactive/lookandfeel/4093793/cubistsept.pdf. Accessed 14 June 2019.
19. Medi-Span drug database. Wholesale acquisition costs pricing. 2019. WoltersKluwer. Available at: https://www.wolterskluwercdi.com/drug-data/average-wac-pricing/. Accessed 14 June 2019.
20. Shields RK, Clancy CJ, Pasculle AW, et al. Verification of ceftazidime-avibactam and ceftolozane-tazobactam susceptibility testing methods against carbapenemresistant Enterobacteriaceae and Pseudomonas aeruginosa. J Clin Microbiol 2018; 56:e01093-17.
21. Shields RK, Potoski BA, Haidar G, et al. Clinical outcomes, drug toxicity, and emergence of ceftazidime-avibactam resistance among patients treated for carbapenem-resistant Enterobacteriaceae infections. Clin Infect Dis 2016; 63:1615-8.
22. Haidar G, Clancy CJ, Shields RK, et al. Mutations in blaKPC-3 that confer ceftazidime-avibactam resistance encode novel KPC-3 variants that function as extended-spectrum beta-lactamases. Antimicrob Agents Chemother 2017; 61e02534-16.
23. Rex JH, Talbot GH, Goldberger MJ, et al. Progress in the fight against multidrugresistant bacteria 2005-2016: modern noninferiority trial designs enable antibiotic development in advance of epidemic bacterial resistance. Clin Infect Dis 2017; 65:141-6.
24. Infectious Diseases Society of America. White paper: recommendations on the conduct of superiority and organism-specific clinical trials of antibacterial agents for the treatment of infections caused by drug-resistant bacterial pathogens. Clin Infect Dis 2012; 55:1031-46.
25. Gandra S, Trett A, Klein EY, Laxminarayan R. Is antimicrobial resistance a bigger problem in tertiary care hospitals than in small community hospitals in the United States Clin Infect Dis 2017; 65:860-3.
26. Petty LA, Henig O, Patel TS, et al. Overview of meropenem-vaborbactam and newer antimicrobial agents for the treatment of carbapenem-resistant Enterobacteriaceae. Infect Drug Resist 2018; 11:1461-72.
27. Pogue JM, Bonomo RA, Kaye KS. Ceftazidime/avibactam, meropenem/vaborbactam, or both Clinical and formulary considerations. Clin Infect Dis 2019; 68:519-24.
28. Bhatti T, Lum K, Holland S, et al. A perspective on incentives for novel inpatient antibiotics: no one-size-fits-all. J Law Med Ethics 2018; 46:59-65.
29. Sciarretta K, Rottingen JA, Opalska A, et al. Economic incentives for antibacterial drug development: literature review and considerations from the transatlantic task force on antimicrobial resistance. Clin Infect Dis 2016; 63:1470-4.